2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
133
Brain Neoplasms
129
Prostatic Neoplasms
108
Neoplasm Metastasis
88
Lung Neoplasms
74
Carcinoma, Hepatocellular
71
Pancreatic Neoplasms
69
Breast Neoplasms
50
Melanoma
44
Carcinoma, Renal Cell
36
Neoplasms
34
Colorectal Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
25
Glioblastoma
24
Liver Neoplasms
20
Head and Neck Neoplasms
17
Small Cell Lung Carcinoma
15
Sarcoma
13
Kidney Neoplasms
13
Glioma
12
Urinary Bladder Neoplasms
10
Recurrence
9
Gliosarcoma
8
Ovarian Neoplasms
7
Central Nervous System Neoplasms
7
Adenocarcinoma of Lung
7
Adenocarcinoma
7
Radiation Injuries
6
Prostate Cancer Metastatic
6
Neuroma, Acoustic
6
Interventions
Ipilimumab
17
tremelimumab
9
Nivolumab
9
durvalumab
8
pembrolizumab
6
Paclitaxel
5
Carboplatin
4
Capecitabine
4
Bevacizumab
4
lenvatinib
3
spartalizumab
2
balstilimab
2
Radiotherapy
2
Radiation
2
Pemetrexed
2
Oxaliplatin
2
Doxorubicin
2
Docetaxel
2
Cisplatin
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tilsotolimod
1
tebentafusp
1
relatlimab
1
poly ICLC
1
osimertinib
1
folfirinox
1
eribulin
1
envafolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Radiosurgery
×
Clear all
NCT05915481
2023-06-23
SCARCE
Peking University Third Hospital
Phase 1/2
Unknown
60 enrolled